News Story: Full Text
Sponsored By
AbbVie
Please Click On The Above Banner For More Details
Braintumor Website

 

ImmunoCellular Therapeutics (IMUC) Announces Presentation of Updated ICT-107 Phase 2 Data in GBM

Al's Comment:

 Amazing long term data presented for the phase 1 trial of ict-107.  This was a small trial (16 patients) for newly diagnosed gbm patients.  Results:19% of patients had long-term remission of greater than 8 years. Also, 38% of patients demonstrated long-term survival of greater than 8 years.  At the time the trial started, expected survival was less than 18 months for standard treatments.   A subsequent larger trial showed early results that was good but not this good.  Hopefully as the data matures, the tail of long term survivors will jack up the average survivals! This is a relatively simple treatment with minimal side effects.


Posted on: 11/21/2016

ImmunoCellular Therapeutics (IMUC) Announces Presentation of Updated ICT-107 Phase 2 Data in GBM

http://www.streetinsider.com/dr/news.php

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740